On September 7, 2021 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Nuvo Pharmaceuticals, SEP 7, 2021, https://www.miravohealthcare.com/news/miravo-healthcare-announces-participation-at-the-h-c-wainwright-23rd-annual-global-investment-conference/ [SID1234587318]). The conference is being held as a virtual conference on September 13-15, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer, will be providing an overview of the Company’s business during the presentation. If you are an institutional or retail investor and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. Over 750 corporate presentations and panels are available live and on-demand on September 13, 2021, starting at 7:00 a.m. ET.

Event: H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

Date: September 13-15, 2021

Time: Available for on-demand viewing starting at 7:00 a.m. ET

Company Webcasting Link: View Source

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.

On September 7, 2021 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported that management will participate in the following investor conferences in the month of September (Press release, Crinetics Pharmaceuticals, SEP 7, 2021, View Source [SID1234587317]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright: 23rd Annual Global Investment Conference (September 13-15, 2021): A pre-recorded company presentation by Dr. Scott Struthers, Founder & CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-on-one meetings at the conference on September 13, 2021.
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event (September 22-23, 2021): Company management will be available for one-on-one meetings on September 22, 2021.
Cantor Fitzgerald Global Healthcare Conference (September 27-30, 2021): Dr. Struthers and Dr. Alan Krasner, CMO, will present on September 27, 2021 at 3:20 pm ET and participate in one-on-one meetings on September 27-28, 2021.
WEBCAST LINKS:
Links to live and archived webcasts will be accessible on the Events & Presentations page in the Investors section on the Company’s website.

On September 7, 2021 Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, reported that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences (Press release, Abeona Therapeutics, SEP 7, 2021, View Source [SID1234587316]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference on September 8-10, 2021 (one-on-one meetings only).

H.C. Wainwright 23rd Annual Global Investment Conference. The pre-recorded presentation will be available beginning September 13, 2021 at 7:00 a.m. ET throughout the conference ending September 15, 2021.

SVB Leerink CybeRx Series Neuromuscular, Rare Diseases & Genetic Medicines on September 22-23, 2021 (one-on-one meetings only).

Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 3:20 p.m. ET.
The company presentations will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replays will be available within 24 hours of the live presentation and will be accessible for 90 days.

On September 7, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences (Press release, Kura Oncology, SEP 7, 2021, View Source [SID1234587315]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 13, 2021; and

A pre-recorded fireside chat at the Cantor Global Healthcare Conference, available at 3:20 p.m. ET / 12:20 p.m. PT on September 27, 2021.
Audio webcasts of the H.C. Wainwright and Cantor events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

On September 7, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 (Press release, Akari Therapeutics, SEP 7, 2021, https://www.akaritx.com/2021/09/07/akari-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference/ [SID1234587314]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the Company’s presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. ET by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event.